About
Articles by Anne Elise Herold
-
Personal Jurisdiction Over Patent Holder in Licensee’s Forum Proper When They Shared Counsel, Communications, and A History of Joint Enforcement
Personal Jurisdiction Over Patent Holder in Licensee’s Forum Proper When They Shared Counsel, Communications, and A History of Joint Enforcement
By Anne Elise Herold Li
-
No Water Fight For You! - Federal Circuit Upholds Preliminary Injunction on Water Balloons Despite PTAB's Decision Invalidating Patent
No Water Fight For You! - Federal Circuit Upholds Preliminary Injunction on Water Balloons Despite PTAB's Decision Invalidating Patent
By Anne Elise Herold Li
-
Federal Circuit Clarifies Level of Threat for DJ jurisdiction
Federal Circuit Clarifies Level of Threat for DJ jurisdiction
By Anne Elise Herold Li
Activity
-
Alexander Berne, Vicente Nunez and Sameer Pai have been awarded 2023 Patent Pro Bono Achievement Certificates by the USPTO. The firm was also awarded…
Alexander Berne, Vicente Nunez and Sameer Pai have been awarded 2023 Patent Pro Bono Achievement Certificates by the USPTO. The firm was also awarded…
Liked by Anne Elise Herold Li
-
As advocates, we must always have our audience in mind. For litigators, that’s usually the judge and the clerk. But the judicial decision-making…
As advocates, we must always have our audience in mind. For litigators, that’s usually the judge and the clerk. But the judicial decision-making…
Liked by Anne Elise Herold Li
-
As a token of appreciation to our LEGENDary team, we had a visit from an ice cream truck at our global headquarters in Somerset, NJ. It was the…
As a token of appreciation to our LEGENDary team, we had a visit from an ice cream truck at our global headquarters in Somerset, NJ. It was the…
Liked by Anne Elise Herold Li
Experience & Education
Licenses & Certifications
Volunteer Experience
Publications
-
Third Circuit Rules That FTC v. Actavis Covers More Than Cash
Antitrust Law Alert
On June, 26, 2015, the U.S. Court of Appeals for the Third Circuit held that non-cash "payments" made by a patentee drug manufacturer to a prospective generic drug manufacturer in exchange for delayed entry of a generic drug is an actionable "reverse payment" and may be subject to antitrust scrutiny under the Supreme Court's decision in FTC v. Actavis, 133 S. Ct. 2223 (2013). King Drug Company of Florence, Inc. v. Smithkline Beecham Corp., et al., Case No. 14-1243 (Smithkline).
Other authorsSee publication -
Third Circuit Rules That FTC v. Actavis Covers More Than Cash
Antitrust Law Alert
On June, 26, 2015, the U.S. Court of Appeals for the Third Circuit held that non-cash "payments" made by a patentee drug manufacturer to a prospective generic drug manufacturer in exchange for delayed entry of a generic drug is an actionable "reverse payment" and may be subject to antitrust scrutiny under the Supreme Court's decision in FTC v. Actavis, 133 S. Ct. 2223 (2013). King Drug Company of Florence, Inc. v. Smithkline Beecham Corp., et al., Case No. 14-1243 (Smithkline).
Other authorsSee publication -
Federal Circuit: 'Molecular Weight' Is Still Indefinite
IP Insights
In a decision applying two recent Supreme Court decisions, the Federal Circuit on Thursday held that the claims to Teva's patents covering the multiple sclerosis drug Copaxone® were invalid for the second time. Teva Pharm.USA, Inc. v. Sandoz, Inc., 2012-1567, slip op. at 18 (Fed. Cir. June 18, 2015). Judge Moore, writing for the court again, found that the claim term "molecular weight" was indefinite because a person of ordinary skill in the art would not understand with reasonable certainty to…
In a decision applying two recent Supreme Court decisions, the Federal Circuit on Thursday held that the claims to Teva's patents covering the multiple sclerosis drug Copaxone® were invalid for the second time. Teva Pharm.USA, Inc. v. Sandoz, Inc., 2012-1567, slip op. at 18 (Fed. Cir. June 18, 2015). Judge Moore, writing for the court again, found that the claim term "molecular weight" was indefinite because a person of ordinary skill in the art would not understand with reasonable certainty to which type of molecular weight the claim language referred.
Other authorsSee publication -
What Sequenom Means for Biotech Patents: Even New Methods of Using Natural Phenomena May Not Be Patentable, Absent More
Intellectual Property Bullet Analyses
On June 12, 2015, in Ariosa Diagnostics, Inc. v. Sequenom, Inc., the U.S. Court of Appeals for the Federal Circuit invalidated Sequenom's patent claiming methods of detecting paternally-inherited fetal DNA in a mother's blood serum or plasma, affirming the district court's decision. The decision highlights that discoveries to new, even "revolutionary," methods of detecting and analyzing naturally occurring phenomena may be ineligible for patent protection under 35 U.S.C. § 101 absent some…
On June 12, 2015, in Ariosa Diagnostics, Inc. v. Sequenom, Inc., the U.S. Court of Appeals for the Federal Circuit invalidated Sequenom's patent claiming methods of detecting paternally-inherited fetal DNA in a mother's blood serum or plasma, affirming the district court's decision. The decision highlights that discoveries to new, even "revolutionary," methods of detecting and analyzing naturally occurring phenomena may be ineligible for patent protection under 35 U.S.C. § 101 absent some additional contribution to the state of the art. In so holding, the court considered and rejected arguments by Sequenom that (1) limited preemption of the natural phenomenon by the claims at issue rendered the claims patent eligible; and (2) that a new application of already known steps or processes to a newly discovered natural phenomenon is itself patent eligible.
Other authorsSee publication -
Federal Circuit Stops the Launch of the First U.S. Biosimilar Pending Appeal
Life Sciences Alert
On Thursday, March 19, 2015, a district court ruling paved the way for the first biosimilar product approved by the U.S. Food and Drug Administration (FDA) to enter the market. Judge Seeborg in the Northern District of California granted a victory to Sandoz in its fight with Amgen, Inc. over Zarxio, Novartis AG's generic version of Amgen Inc.'s cancer drug Neupogen® (the "reference product") by denying Amgen's request for a preliminary injunction. In the order, the court sided with Sandoz on…
On Thursday, March 19, 2015, a district court ruling paved the way for the first biosimilar product approved by the U.S. Food and Drug Administration (FDA) to enter the market. Judge Seeborg in the Northern District of California granted a victory to Sandoz in its fight with Amgen, Inc. over Zarxio, Novartis AG's generic version of Amgen Inc.'s cancer drug Neupogen® (the "reference product") by denying Amgen's request for a preliminary injunction. In the order, the court sided with Sandoz on its interpretation of the portion of the Biologics Price Competition and Innovation Act (BPCIA) governing the disclosure requirements imposed on biosimilar manufacturers prior to sale of a biosimilar product. The court also rejected Amgen's interpretation of the statute that would have required Sandoz to wait 180 days from approval of the biosimilar product before going to market. Amgen (the "reference product sponsor") has said that it will appeal the ruling.
Other authorsSee publication -
Using Numbers to Win Your Case – the Persuasive Presentation of Statistical Evidence
World Trademark Review
Honors & Awards
-
Super Lawyers New York Rising Star in Intellectual Property 2014
-
-
Super Lawyers New York Rising Star in Intellectual Property 2013
-
-
Thurgood Marshall Award
Bar of the City of New York
In recognition of work as pro bono counsel to an individual under sentence of death.
-
Archibald Murray Public Service Award, summa cum laude
Fordham University School of Law
-
Anthrax Outbreak - Certificate of Completion
Centers for Disease Control
-
Super Lawyers New York Rising Star in Intellectual Property 2015
-
More activity by Anne Elise Herold
-
Crowell & Moring’s Amanda Shafer Berman Berman weighs in on the future litigation landscape in the wake of the Supreme Court’s overrule of the…
Crowell & Moring’s Amanda Shafer Berman Berman weighs in on the future litigation landscape in the wake of the Supreme Court’s overrule of the…
Shared by Anne Elise Herold Li
-
Crowell & Moring white collar attorneys write in the New York Law Journal on the SEC’s latest remarks on effective corporate cooperation in SEC…
Crowell & Moring white collar attorneys write in the New York Law Journal on the SEC’s latest remarks on effective corporate cooperation in SEC…
Shared by Anne Elise Herold Li
-
Joanna Rosen Forster joined Crowell & Moring’s Litigation Group in San Francisco as a partner, with “a reputation as a ‘Swiss Army knife style of…
Joanna Rosen Forster joined Crowell & Moring’s Litigation Group in San Francisco as a partner, with “a reputation as a ‘Swiss Army knife style of…
Shared by Anne Elise Herold Li
-
We welcome partner Joanna Rosen Forster to our Litigation Group in San Francisco. Joanna brings nearly two decades of experience ranging from…
We welcome partner Joanna Rosen Forster to our Litigation Group in San Francisco. Joanna brings nearly two decades of experience ranging from…
Shared by Anne Elise Herold Li
-
I am proud to say that my partner, Leslie J. Lott, and I have been selected as Florida Super Lawyers in Intellectual Property in 2024. I am also very…
I am proud to say that my partner, Leslie J. Lott, and I have been selected as Florida Super Lawyers in Intellectual Property in 2024. I am also very…
Liked by Anne Elise Herold Li
-
Wow, Garylene "Gage" Javier, Aaron Cummings. Way to represent
Wow, Garylene "Gage" Javier, Aaron Cummings. Way to represent
Shared by Anne Elise Herold Li
-
Crowell & Moring’s Lisa Henneberry discusses Mexico’s increased reliance on natural gas to support electricity demand. Read more in POWER Magazine:
Crowell & Moring’s Lisa Henneberry discusses Mexico’s increased reliance on natural gas to support electricity demand. Read more in POWER Magazine:
Shared by Anne Elise Herold Li
People also viewed
-
Deborah Yellin
Partner at Crowell & Moring LLP
Connect -
Paul Keller
Connect -
Shannon Lentz
Partner at Crowell & Moring LLP
Connect -
Kathryn Jones
Connect -
Preetha Chakrabarti
Connect -
Michelle Chipetine
Counsel at Crowell & Moring LLP
Connect -
Lisa Gistis
Connect -
Mark Remus
Connect -
Laura Lydigsen
Intellectual Property Attorney at Crowell & Moring LLP
Connect -
Toni Michelle Jackson
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More